Boric Acid (99.9% Granular) - Peru CAS: 10043-35-3
Related Insights
CPI's Steepest Drop in Six Years: What Lower Inflation Means for Chemical Regulatory Cost Assessments
June's 0.4% decline in the Consumer Price Index marked the largest monthly drop in more than six years, creating new considerations for chemical regulatory cost assessments. Procurement and compliance teams should understand how inflation trends influence regulatory analysis and future compliance costs.
CSRD and Chemical Supply Chain Due Diligence: How Ownership Transfers Affect Scope 3 Data
Supplier ownership changes can create unexpected challenges for Scope 3 emissions reporting under the Corporate Sustainability Reporting Directive. This guide explains how procurement and sustainability teams should manage supplier data continuity following ownership transfers.
Sustainability in Chemical Procurement: Frameworks, Standards, and What "Credible" Looks Like
Sustainability claims have become common across the chemical industry, but not all certifications provide the same level of assurance. This guide explains the leading sustainability frameworks and helps procurement teams evaluate supplier claims with greater confidence.
Tropical Storm Arthur and Gulf Coast Chemical Disruption: What It Means for Corn Starch, Glucose and Dextrose Supply
Tropical Storm Arthur has renewed attention on Gulf Coast supply chain risk just as the 2026 Atlantic hurricane season begins. Find out how refinery shutdowns, logistics disruptions and weather uncertainty could affect procurement strategies for corn starch, glucose and dextrose buyers during the second half of 2026.
Heparin and Biologics Raw Materials: Supply Chain Review and Procurement Outlook for H2 2026
The biologics supply chain remained resilient through H1 2026 despite higher logistics costs. As heparin production stays concentrated and biologics demand grows, procurement teams should focus on diversification, quality assurance, and long-term supplier partnerships.
Pharmaceutical Supply Chain: H1 2026 Closing Risk Assessment
The first half of 2026 exposed major vulnerabilities in pharmaceutical supply chains. API concentration, shipping disruptions, and logistics risks are reshaping procurement strategies for H2 2026 and beyond.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.